Morgan Stanley
ACTU

Morgan Stanley’s Actuate Therapeutics ACTU Stock Holding History

Morgan Stanley’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.34K Sell
3,490
-3,392
-49% -$7.86K ﹤0.01% 7195
2026
Q1 		$18.9K Sell
6,882
-6,237
-48% -$25.8K ﹤0.01% 6751
2025
Q4 		$80.3K Buy
13,119
+5,493
+72% +$37.7K ﹤0.01% 6279
2025
Q3 		$51K Sell
7,626
-114
-1% -$826 ﹤0.01% 6388
2025
Q2 		$47.3K Buy
7,740
+6,202
+403% +$54.2K ﹤0.01% 6376
2025
Q1 		$10.4K Buy
1,538
+996
+184% +$8K ﹤0.01% 6784
2024
Q4 		$4.31K Buy
+542
New +$4.42K ﹤0.01% 7044

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Morgan Stanley's ACTU Position: Q2 2026 in Review

Morgan Stanley reduced its Actuate Therapeutics (ACTU) stake by 49% in Q2 2026, selling an estimated $7.86K and leaving 3,490 shares worth $5.34K. The position accounts for ﹤0.01% of the portfolio, ranked #7195.

Morgan Stanley first reported a position in ACTU in Q4 2024 and has held it in 7 quarters since. The position peaked at $80.3K in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Morgan Stanley held 3,490 shares of Actuate Therapeutics worth $5.34K as of Q2 2026.
  • Morgan Stanley sold 3,392 Actuate Therapeutics shares in Q2 2026, an estimated $7.86K.
  • Actuate Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7195 holding.
  • Morgan Stanley first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Actuate Therapeutics position peaked at $80.3K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.